TABLE 3.
Sensitivity analysis of the relationship between β-blockers use and 28-day mortality.
| Variable | Crude HR (95%CI) | P value | Adjusted HR (95%CI) a | P value |
|---|---|---|---|---|
| Non-CHF and Non- hypertension | 0.46 (0.28–0.78) | 0.003 | 0.35 (0.20–0.61) | <0.001 |
| Metoprolol | 0.64 (0.46–0.89) | 0.008 | 0.49 (0.34–0.68) | <0.001 |
| Other type β-blockers | 0.21 (0.07–0.66) | 0.007 | 0.26 (0.07–0.91) | 0.0036 |
| Oral administration | 0.41 (0.27–0.61) | <0.001 | 0.39 (0.25–0.61) | <0.001 |
| Intravenous administration | 0.77 (0.50–1.16) | 0.212 | 0.48 (0.31–0.75) | 0.001 |
a
Multivariate COX, model adjusted for confounders.
Confounding variables are those listed in Supplementary Table S4 that have a P value of less than 0.05. HR, hazard ratio; 95% CI, 95% confidence interval.